Relationship between the concentration and antiatherogenic activity of high-density lipoproteins

Current Opinion in Lipidology

Volumn 17, Issue 4, 2006, Pages 399-403

  Barter, Philip J ^a,b   Rye, Kerry Anne ^a,b,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atherosclerosis; High density lipoproteins; Subpopulations

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; ATP BINDING CASSETTE TRANSPORTER G1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; RECOMBINANT HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTERITIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG INFUSION; EFFUSION; HEART PROTECTION; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; VASCULITIS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, HDL; RISK;

EID: 33746031787     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000236365.40969.af     Document Type: Review

References (36)

1. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256:2835-2838.
2. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241.
3. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94:713-717.
4. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
5. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145:227-238.
6. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113:589-597.
7. Asztalos BF. HDL Atherosclerosis Treatment Study: High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. Curr Opin Cardiol 2004; 19:385-391.
8. Warden CH, Hedrick CC, Qiao JH, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-I. Science 1993; 261:469-472.
9. Amouyel P, Isorez D, Bard JM, et al. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 1993; 13:1640-1644.
10. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into prebeta-migrating high-density lipoprotein. Biochemistry 1988; 27:25-29.
11. Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1:121-131. This study establishes that the ABCG1-mediated efflux of cholesterol to mature HDL particles is an important process for removing cholesterol from macrophages.
12. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25:2185-2191. In this analysis of the VA-HIT study it is shown that the HDL subpopulation that contains the largest HDL particles is the one most closely associated with protection against cardiovascular events.
13. Yang Y, Yan B, Fu M, et al. Relationship between plasma lipid concentrations and HDL subclasses. Clin Chim Acta 2005; 354:49-58. This study confirms previous observations that higher levels of HDL-C are associated with higher levels of large HDL particles.
14. Wang N, Tall AR. Regulation and mechanism of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:1178-1184.
15. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:712-719.
16. Ji Y, Jian B, Wang N, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997; 272: 20982-20985.
17. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004; 101:9774-9779.
18. Nakamura K, Kennedy MA, Baldan A, et al. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J Biol Chem 2004; 279:45980-45989.
19. Asztalos BF, de la Llera-Moya M, Dallal GE, et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 2005; 46:2246-2253. In an analysis of what predicts the efflux of cholesterol from cells it was found that small, lipid-poor, pre-β migrating HDLs have the strongest association with ABCA1-mediated cholesterol efflux, whereas cholesterol efflux via the SR-BI pathway was associated with several HDL subpopulations of differing apolipoprotein composition, lipid content, and size.
20. Gelissen IC, Harris M, Rye KA, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26:534-540. This study suggests that an ABCA1-mediated efflux of lipids to lipid-free apoA-I generates particles that are then capable of acting as acceptors of the cholesterol efflux promoted by ABCG1.
21. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 2005; 280:30150-30157. This study described a novel function of ABCG1. It was found that in the absence of extracellular lipoproteins, ABCG1 moves to the plasma membrane, where it redistributes membrane cholesterol to cell surface domains to become accessible for removal by HDL.
22. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003; 6:179-188.
23. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25:1057-1064.
24. Cockerill GW, Rye K-A, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987-1994.
25. Baker PW, Rye K-A, Gamble JR, et al. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999; 40: 345-353.
26. Dimayuga P, Zhu J, Oguchi S, et al. Reconstituted HDL containing human apolipoprotein A-I reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Comm 1999; 264:465-468.
27. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001; 104:2447-2452.
28. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005; 25:2416-2421. Three intravenous infusions of relatively small amounts of either native HDLs or rHDLs into rabbits with experimental atherosclerosis reduced the extent of atherosclerosis and inhibited endothelial inflammation.
29. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103: 108-112.
30. Paterno R, Ruocco A, Postiglione A, et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004; 17:204-211.
31. Cockerill GW, McDonald MC, Mota-Filipe H, et al. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 2001; 15:1941-1952.
32. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111:1543-1550. In a model of acute arterial inflammation in rabbits, infusions of small amounts of either rHDLs or lipid-free apoA-I resulted in a profound inhibition of the arterial inflammation. This effect was seen without a measurable increase in concentration of HDL-C in plasma.
33. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005; 97:763-771. It was concluded from these in-vivo studies of mice that apoA-I inhibits atherosclerosis by promoting both macrophage reverse cholesterol transport and HDL anti-inflammatory function and that these functions are largely independent of the plasma concentration of HDL-C.
34. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 2005; 97:524-532. This study describes the beneficial effects of small oral peptides on atherosclerosis in apoE -/- mice and their favourable influence on the inflammatory/anti-inflammatory properties of HDLs in mice and monkeys.
35. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331. This review provides a comprehensive summary of many studies from this group investigating the antiatherogenic and HDL-modifying effects of apoA-I mimetic peptides.
36. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15:158-161.